8-K: Decoy Therapeutics Sets 2026 Annual Meeting Date
Annual Meeting Announcement
Decoy Therapeutics Inc. announced its 2026 Annual Meeting of Stockholders will be held on July 14, 2026, with specific deadlines for shareholder proposals and director nominations.
Summary
- Decoy Therapeutics Inc. has scheduled its 2026 Annual Meeting of Stockholders for July 14, 2026.
- The record date for stockholders entitled to notice and voting rights is May 22, 2026.
- Shareholders wishing to submit proposals for inclusion in the proxy materials must do so by May 29, 2026, adhering to SEC Rule 14a-8 and company bylaws.
- Shareholders intending to nominate directors or present business outside of Rule 14a-8 must also notify the company by May 29, 2026.
- Notice for proxy solicitation in support of director nominees other than the company's must be provided by May 29, 2026, in compliance with Rule 14a-19.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, primarily procedural, with no new financial or strategic information provided.
Positives
- Clear communication of the annual meeting date provides shareholders with advance notice for planning.
- Established deadlines for proposals and nominations allow for orderly corporate governance processes.
Risks
- Failure to meet the May 29, 2026, deadline for proposals or nominations could disenfranchise shareholders.
- Complexity of SEC rules (Rule 14a-8, Rule 14a-19) and company bylaws may pose challenges for individual shareholders submitting proposals.
Future Outlook
The company will file its proxy statement with the SEC prior to the 2026 Annual Meeting, which will contain details on time, location, and other meeting specifics.
Industry Context
StockSavvy.ai notes that setting annual meeting dates and associated deadlines is a standard procedural requirement for publicly traded companies, crucial for maintaining transparent corporate governance and facilitating shareholder engagement.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Annual Meeting Date | Established July 14, 2026, as the date for the 2026 Annual Meeting of Stockholders. | May 19, 2026 | Standard procedural update, allows for shareholder planning. |
| Shareholder Proposal Deadlines | Set deadlines for submitting proposals for inclusion in proxy materials (Rule 14a-8) and for bringing business outside of Rule 14a-8 or nominating directors. | May 29, 2026 | Ensures timely processing of shareholder input and nominations, aligns with regulatory requirements. |
| Universal Proxy Rule Compliance | Established deadline for notice regarding solicitation of proxies for director nominees other than company nominees (Rule 14a-19). | May 29, 2026 | Facilitates compliance with universal proxy rules, impacting proxy contests. |
Stakeholder Impact
- Shareholders: Provided with a clear timeline for the annual meeting and deadlines for submitting proposals or director nominations, enabling participation in corporate governance.
- Management: Must adhere to the established timelines for proxy material preparation and shareholder engagement.
Next Steps
- Filing of the company's proxy statement for the 2026 Annual Meeting with the SEC.
- Shareholders to submit proposals or nominations by the specified deadlines.
- Conducting the 2026 Annual Meeting of Stockholders on July 14, 2026.
Key Dates
| Date | Description |
|---|---|
| May 19, 2026 | Date of Report (Date of earliest event reported) |
| May 22, 2026 | Record date for stockholders entitled to notice of and to vote at the 2026 Annual Meeting. |
| May 29, 2026 | Deadline for submission of stockholder proposals for inclusion in proxy materials (Rule 14a-8). |
| May 29, 2026 | Deadline for stockholders to deliver notice for business outside of Rule 14a-8 or to nominate directors. |
| May 29, 2026 | Deadline for stockholders intending to solicit proxies for director nominees other than company nominees (Rule 14a-19). |
| July 14, 2026 | Date of the Company's 2026 Annual Meeting of Stockholders. |
Keywords
Annual Meeting, Shareholder Proposals, Director Nominations, Proxy Statement, Corporate Governance, SEC Filings, Decoy Therapeutics, Rule 14a-8
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.